Research listings · GLP-1 research listings
Semaglutide research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · How we check prices →
Semaglutide listings
No single-substance listings are tracked for Semaglutide yet.
Research context
From our own records, with the date each was last checked.
- FDA approval
- Approved under NDAs: Ozempic injection (first approved 2017-12-05), Rybelsus (2019-09-20), Wegovy injection (2021-06-04), Wegovy tablets (2025-12-22), Ozempic tablets (2026-01-30)Checked
- 503A / 503B compounding
- Shortage resolved 2025-02-21; compounder wind-down ended in April 2025 (503A) and on 2025-05-22 (503B); not on the 503B bulks listChecked
- Advisory committee (PCAC)
- Pending editor checkChecked
- Rulemaking / enforcement
- FDA proposed not to include it on the 503B bulks list (notice 2026-05-01; comments extended to 2026-07-30); no final notice found by 2026-11-03Checked
- Human studies
- 1 recorded
- Identity
- Formula C187H291N45O59 · MW 4114 g/mol · CAS 910463-68-2Source record Checked
Identity noteResearch listings are not Ozempic, Wegovy or Rybelsus. They are not FDA-approved medicines and are not made or checked by the company that makes those products.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.